We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Oncolytics Biotech® Inc. Announces Second Quarter 2011 Results

News   Aug 01, 2011

 
Oncolytics Biotech® Inc. Announces Second Quarter 2011 Results
 
 
Advertisement
 

RELATED ARTICLES

Prioritizing Drugs Targeting IFNAR2 and ACE2 To Treat COVID-19

News

Researchers have used human genetics in a new study and the findings suggest researchers should prioritize clinical trials of drugs that target the proteins IFNAR2 and ACE2 to manage COVID-19 in its early stages.

READ MORE

Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types

News

Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and demonstrated potential clinical benefit in patients with diverse tumor types according to a Phase 1 study. The findings were reported during the virtual AACR Annual Meeting 2021.

READ MORE

Phase 1 Study of Novel Oral Antiviral Against SARS-CoV-2 Initiated

News

Pfizer's oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, is progressing to Phase 1 testing following preclinical testing demonstrating potent in vitro anti-viral activity against SARS-CoV-2.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE